CUSIP: 88369M101
Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
35,194,795
-
Share change
-
-4,667,878
-
Total reported value
-
$94,671,533
-
Price per share
-
$2.69
-
Number of holders
-
62
-
Value change
-
-$58,405,910
-
Number of buys
-
29
-
Number of sells
-
35
Quarterly Holders Quick Answers
What is CUSIP 88369M101?
CUSIP 88369M101 identifies THRX - THESEUS PHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2023
-
Previous quarter:
Q2 2023
Recent filing periods for CUSIP 88369M101:
Institutional Holders of THESEUS PHARMACEUTICALS INC - COM (THRX) as of Q3 2023
As of 30 Sep 2023,
THESEUS PHARMACEUTICALS INC - COM (THRX) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,194,795 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Foresite Capital Management V, LLC, Frazier Life Sciences Management, L.P., MILLENNIUM MANAGEMENT LLC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, Omega Fund Management, LLC, Lynx1 Capital Management LP, and Nextech Invest Ltd..
This page lists
62
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.